March 22, 2016 - Curant COO, Marc O'Connor, in MedCity News - We have long known that improvements in medication adherence are the longest lever available to impact wasteful healthcare spending in the United States. We know further that improvements in adherence affect both variables of the value equation in the right direction: improving outcomes and […]
There are a number of items that influence medication spend, including specialty drug costs, medication adherence and patient outcomes. However, there’s another item out there that may be driving up medication cost unnecessarily. What we know There are 3 well-known drivers that contribute to medication spending in the U.S.: Massive increase in number and cost […]
[vc_row][vc_column][vc_column_text]Curant Health President and CEO, Patrick Dunham, and Curant Health pharmacist, Jeffrey Karkula, RPh, BS Pharm, recently conducted a study to identify the benefits of a comprehensive pharmacy care program and to increase adherence for patients taking highly active antiretroviral therapy or (HAART) and assess the effect on the patient’s overall health outcome. There are […]
March 8, 2016 - Curant COO, Marc O'Connor, in Managed Healthcare Executive - At its simplest, the top three factors impacting medication spending are the massive increases in number and cost of specialty medications, the backlog of generics awaiting FDA approval and lack of medication adherence. According to a recent presentation delivered to the Pharmaceutical […]
There is a spotlight trained on the constant tug of war currently ongoing between payer and manufacturers regarding at-risk negotiations and drug costs. In the background, pharmacists are frequently left solo to handle the prior authorization and to ensure patient access to necessary medication. According to a November 2015 report from The Pew Charitable Trusts, […]
When it comes to treating population health, there is nothing that can replace the value of a real-life, caring person inquiring about a patient’s feelings, opinions and thoughts in order to identify barriers to medication access and adherence. Why is that? The square root of population health is the health of the individual patient. We’ve […]
There were two prevailing topics that dominated this year’s 340B Coalition Winter Conference: mega-guidance and 340B entity audits. While these terms are not mutually exclusive, they each received significant airtime throughout the conference. The mystery of mega-guidance According to 340B Health, mega-guidance (aka omnibus guidance) is a ruling designed to be a ‘one-stop-shop’ of 340B-related […]
February 29, 2016 - Curant President and CEO, Patrick Dunham, with Curant Senior Director of Pharmacy, David Carver, in Becker's Healthcare - Population health has always seemed like a unicorn to me. Every day I witness exactly what is required to positively impact outcomes for patients with chronic conditions. There is no silver bullet, no patient […]
The increase of specialty drug costs is something that cannot be denied or ignored. According to a study done by the Kaiser Family Foundation and Truven Health Analytics, prescription drug spending accounts for 10% of the national spending on healthcare. The percentage is even higher for self-insured employers. Let’s talk about the two consequences, one […]
February 22, 2016 - Curant COO, Marc O'Connor, in Specialty Pharmacy Times - According to a November 2015 report from The Pew Charitable Trusts, Specialty Drugs and Health Care Costs, in 2014, less than 1% of all prescriptions were written for specialty drugs, yet they accounted for approximately 32% of total drug expenditures. And the […]
